Tariffs drive some health plans to hike premiums

Health insurers are notifying states that tariffs are expected to drive up premiums for individual and small group market enrollees in 2025, adding uncertainty to healthcare costs amid potential Medicaid cuts and expiring ACA subsidies. Independent Health in New York projects a 38.4% premium increase, with 3% attributed to tariffs, while UnitedHealthcare of Oregon cites nearly 3% of its 19.8% small group premium increase to tariff uncertainty, particularly regarding pharmaceutical prices. While some insurers are factoring tariffs into their rates, others, like Kaiser Foundation Health Plan of the Northwest, are holding off, pending further clarity, with final ACA marketplace plan rates due to federal regulators by July 16.

Analysis

Health insurers are signaling significant premium increases for the upcoming year in individual and small group markets, directly attributing a portion of these hikes to anticipated cost escalations from U.S. trade tariffs. This development introduces further uncertainty into the healthcare cost landscape, already unsettled by potential Medicaid cuts and the expected sunsetting of enhanced Affordable Care Act (ACA) subsidies. For instance, Independent Health Benefits Corporation in New York has filed for a 38.4% premium increase for its individual market enrollees, with approximately 3 percentage points of this rise linked to projected tariff impacts on drug prices. Similarly, UnitedHealthcare of Oregon indicated that nearly 3% of its planned 19.8% premium increase for small group plans is a direct consequence of tariff-related uncertainty, particularly concerning pharmaceutical prices. Insurers face a challenging environment, as they must set annual premiums in advance without historical precedent for the current tariff regime and with President Trump suggesting sector-specific pharmaceutical tariffs could be imminent. While some insurers are proactively incorporating these potential costs into their rate filings to mitigate risk, as they cannot adjust premiums mid-year, others, such as Kaiser Foundation Health Plan of the Northwest, are adopting a more cautious stance by not yet factoring in tariff impacts due to prevailing uncertainties. The situation is further complicated by the possibility of hospitals seeking to renegotiate contracts if their own costs surge due to tariffs. State regulators retain the ability to scrutinize and potentially reject proposed premium increases. A clearer industry-wide perspective on the tariff impact is anticipated when insurers submit their 2026 ACA marketplace plan rates to federal regulators by July 16, with proposed rates becoming public by August 1. The overall sentiment is moderately negative, reflecting the compounding cost pressures and operational uncertainties for health insurers.

Key Decisions for Investors

• Investors should closely monitor health insurers' upcoming rate filings, particularly those with significant exposure to individual and small group markets, to assess the magnitude of tariff-driven premium adjustments and their potential impact on enrollment and profitability.
• Pay specific attention to the federal ACA marketplace plan rate submissions due by July 16 and released by August 1 for the 2026 plan year, as these will provide a more comprehensive view of how insurers are pricing in tariff risks across the sector.
• Evaluate individual insurer strategies regarding tariff uncertainty; some may aggressively price-in risks leading to potential market share loss if competitors are less cautious, while others adopting a wait-and-see approach face margin pressure if costs escalate beyond unadjusted premiums.
• For UnitedHealth Group (UNH), note the moderately negative sentiment and the specific instance of its Oregon subsidiary attributing part of a significant premium hike to tariffs, warranting scrutiny of its broader risk mitigation strategies in this segment.
• Consider the broader inflationary pressures on the healthcare sector stemming from trade policies, which could affect not only insurers but also pharmaceutical companies, medical device manufacturers, and hospital systems.